College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang 150081, China.
Key Laboratory of Tropical Translational Medicine of Ministry of Education, College of Biomedical Information and Engineering, Hainan Women and Children's Medical Center, Hainan Medical University, Haikou, Hainan 571199, China.
Nucleic Acids Res. 2023 Jan 6;51(D1):D409-D417. doi: 10.1093/nar/gkac776.
Cancer-related epitopes can engage the immune system against tumor cells, thus exploring epitopes derived from non-coding regions is emerging as a fascinating field in cancer immunotherapies. Here, we described a database, IEAtlas (http://bio-bigdata.hrbmu.edu.cn/IEAtlas), which aims to provide and visualize the comprehensive atlas of human leukocyte antigen (HLA)-presented immunogenic epitopes derived from non-coding regions. IEAtlas reanalyzed publicly available mass spectrometry-based HLA immunopeptidome datasets against our integrated benchmarked non-canonical open reading frame information. The current IEAtlas identified 245 870 non-canonical epitopes binding to HLA-I/II allotypes across 15 cancer types and 30 non-cancerous tissues, greatly expanding the cancer immunopeptidome. IEAtlas further evaluates the immunogenicity via several commonly used immunogenic features, including HLA binding affinity, stability and T-cell receptor recognition. In addition, IEAtlas provides the biochemical properties of epitopes as well as the clinical relevance of corresponding genes across major cancer types and normal tissues. Several flexible tools were also developed to aid retrieval and to analyze the epitopes derived from non-coding regions. Overall, IEAtlas will serve as a valuable resource for investigating the immunogenic capacity of non-canonical epitopes and the potential as therapeutic cancer vaccines.
癌症相关表位可以与免疫系统针对肿瘤细胞,因此探索来自非编码区域的表位正成为癌症免疫治疗中的一个热门领域。在这里,我们描述了一个数据库,IEAtlas(http://bio-bigdata.hrbmu.edu.cn/IEAtlas),旨在提供和可视化人类白细胞抗原(HLA)呈递的免疫原性表位的综合图谱,这些表位来自非编码区域。IEAtlas 重新分析了基于质谱的 HLA 免疫肽组数据集,以获得我们综合基准的非规范开放阅读框信息。目前的 IEAtlas 确定了 245870 个非规范表位,这些表位与 HLA-I/II 同种型结合,跨越 15 种癌症类型和 30 种非癌组织,大大扩展了癌症免疫肽组。IEAtlas 还通过几种常用的免疫原性特征进一步评估了免疫原性,包括 HLA 结合亲和力、稳定性和 T 细胞受体识别。此外,IEAtlas 还提供了表位的生化特性以及对应基因在主要癌症类型和正常组织中的临床相关性。还开发了几个灵活的工具来辅助检索和分析来自非编码区域的表位。总的来说,IEAtlas 将成为研究非规范表位免疫原性和作为治疗性癌症疫苗的潜力的有价值资源。